Digital Therapeutics After Pear: What DTx Companies Must Learn

Why did early digital therapeutics struggle despite strong clinical promise?

Digital therapeutics (DTx) entered the market with enormous ambition. The idea of software delivering clinically validated therapeutic outcomes captured investor, clinician, and regulator attention. But early pioneers struggled not due to lack of clinical potential — but due to business realities.

The early DTx companies underestimated reimbursement complexity, overestimated scaling speed, and relied heavily on direct-to-consumer strategies that couldn’t sustain long-term evidence generation.

The result wasn’t the failure of the model — but a reset of expectations.

What changed in the DTx landscape after those early setbacks?

The industry learned that real success requires three things:
rigorous evidence, regulatory alignment, and viable reimbursement pathways.

In 2025, DTx companies prioritise:

• Robust clinical validation
• Real-world outcome collection
• Long-term adherence strategies
• Partnerships with payers and pharma
• Integration into clinical workflows
• Clear patient benefit narratives

The field has matured from “apps as therapy” to “evidence-based digital interventions.”

How did reimbursement become the decisive factor?

DTx can only scale when payers recognise and fund them.
However, early companies treated reimbursement as an afterthought — focusing instead on awareness campaigns or consumer marketing.

The successful companies today start with:

• Defined ICD or therapeutic pathways
• Demonstration of measurable outcomes
• Ties to existing standards of care
• Pilot data showing reduced cost or burden

Reimbursement is no longer the end of the journey.
It is the foundation.

What role do pharma partnerships now play?

Pharma companies are increasingly turning to DTx to extend therapeutic value, support patient engagement, and differentiate treatments.

For DTx companies, pharma partnerships offer:

• Access to clinical expertise
• Commercial distribution
• Shared regulatory capabilities
• Capital for evidence development
• Integrated care models

Today’s DTx landscape is more collaborative than competitive.

Why is long-term engagement now a core design requirement?

Digital therapeutics work only when patients use them consistently.
That means UX design, behavioural science, and personalisation must complement clinical evidence.

Successful products use:

• Progressive goal-setting
• Nudges based on user patterns
• Adaptive content
• Gamification calibrated for clinical seriousness
• Support loops involving clinicians or coaches

In DTx, adherence isn’t an outcome — it’s an input.

How can DTx companies build durable business models?

A sustainable DTx company in 2025 must:

• Prove cost savings or clinical improvement
• Demonstrate adherence
• Offer seamless integration with provider systems
• Maintain regulatory-grade documentation
• Localise for multiple markets
• Diversify revenue beyond a single pathway

The winners combine clinical strength with operational excellence.

What does the future of digital therapeutics look like?

The field is entering a more stable, evidence-led phase.
Regulators understand it better.
Payers are more receptive.
Providers see value when implementation is smooth.

The companies that thrive will be those that treat digital therapeutics like medicine — designed rigorously, studied thoroughly, and delivered with empathy.

‍